Introduction
Primary hemostasis, secondary hemostasis and the fibrinolytic system are the three main components of blood coagulation. These complex processes are integrated to serve a major common goal to stop unwanted bleeding and to prevent unnecessary clot formation. This review focuses on the fibrinolytic process, particularly on the hemorrhagic diathesis, which occurs when the fibrinolytic pathway is accelerated. In general, fibrinolysis is the process of fibrin clot solubilization. This process is accurately regulated by activators, inhibitors and cofactors to maintain a delicate balance. An overview of this balance is illustrated in Fig. 1 . The key component of fibrinolysis is plasmin, a serine protease that degrades fibrin. The zymogen plasminogen is the pro-enzyme for plasmin and can be converted by tissue-type plasminogen activator (tPA) or urokinase-type plasminogen activator (uPA). tPA is synthesized and secreted primarily by endothelial cells, and its release is regulated by multiple stimuli, including thrombin [1] [2] [3] . In the absence of fibrin, tPA is a very weak activator of plasminogen; however, its catalytic efficiency is greatly enhanced in the presence of fibrin. In this situation fibrin stimulates its own degradation [3] . uPA can effectively activate plasminogen both in presence and absence of fibrin but has much lower affinity for fibrin as compared with tPA [1, 3] . Once formed, plasmin cleaves fibrin, generating fibrin degradation products (FDP) [1] . Inhibitors, on the other hand, are present to balance the fibrinolytic homeostasis. Thrombin-activatable fibrinolysis inhibitor (TAFI) attenuates plasmin generation after being activated by thrombin, plasmin or thrombomodulin-bound thrombin. TAFI removes the carboxy-terminal lysine residues from fibrin, resulting in a decreased plasmin generation and stabilization of fibrin containing thrombi [1, 3] . Plasminogen activator inhibitor type 1 (PAI-1) is an inhibitor of tPA and uPA. Inhibitors of plasmin are a2-antiplasmin (a2-AP) and a2-macroglobulin (a2-M). The main physiological plasmin inhibitor is a2-AP. In the situation when plasmin is formed in excess in respect to a2-AP, plasmin is neutralized by a2-M [2] . Figure 2 illustrates the interplay between activators and inhibitors of fibrinolysis in vivo upon formation of a fibrin clot after damage of the endothelium. Pathophysiological conditions of fibrinolysis with an increased risk of bleeding disorders are a decreased inhibition of fibrinolysis as a result of deficiency of one of the main inhibitors (a2-AP and PAI-1) or an increase in plasminogen activation as a result of excess tPA or uPA. The abundant presence of uPA can be caused by increased expression of uPA in platelets, known as Quebec platelet disorder.
Deficiency of TAFI would theoretically lead to hyperfibrinolysis because of decreased inhibition of the fibrinolytic pathway but has never been described in literature. TAFI-deficient mice did not show a bleeding tendency [4] . On the contrary, high levels of TAFI have been described in patients with a bleeding tendency [5] . However, because TAFI is activated by thrombin, coagulation disorders leading to decreased formation of thrombin can cause decreased activation of TAFI, leading to hyperfibrinolysis. It is suggested that this contributes to the bleeding phenotype in patients with a coagulation factor deficiency, as in hemophilia or in factor XI deficiency [6, 7] .
Diagnosis of a hyperfibrinolytic bleeding tendency is challenged by the lack of currently available and validated laboratory tests. A difficulty in the development of a fibrinolysis screening assay is the low baseline fibrinolytic capacity as a result of the presence of fibrinolysis inhibitors in plasma. This can be partially resolved by acidification of the plasma, shifting the plasma to a more fibrinolytic nature (less PAI-1 dependent) [8] . One of the most frequently used laboratory screening assays is the euglobulin clot lysis time (ECLT), recording the time till visual lysis of the euglobulin fraction in a tube. It is usually shortened in cases of increased fibrinolysis. However, because of a lack of global validation, a normal euglobulin clot lysis time does not exclude hyperfibrinolysis. Thromboelastography (TEG) and rotation thromboelastometry (ROTEM) assess viscoelastic changes after recalcification and addition of coagulation activators to citrated whole blood. They are mainly used as point-ofcare coagulation tests in massive blood loss in the emergency department or in the operating room. However, their reproducibility is poor and they require specialized equipment [9] . Plasma turbidity assays measure changes in optical density after the initiation of coagulation. They are sensitive for plasma levels of all fibrinolytic proteins except for tPA, as tPA is added to induce lysis [10] . Prolonged plasma clot lysis times measured by this method are associated with hypofibrinolysis and have been shown to increase the risk of venous and arterial thrombosis. Shortened clot lysis times, on the other hand, may reflect various hemorrhagic states induced by hyperfibrinolysis [9, 10] . The global fibrinolytic capacity in whole blood is another assay of fibrinolysis. An advantage of this method is that no fibrinolysis activators are added. This assay is sensitive for abnormalities in t-PA activity, PAI-1 activity, fibrinogen and TAFI activity [9, 11] . Global assays may be helpful in the future; however, they are not available for clinical use at the moment. TAFI, a2-AP, PAI-1, tPA and uPA can all be measured in blood using confirmation assays and allow quantification of antigen and activity levels, but these assays are not available in every laboratory and there is no consensus about the cutoff level to define deficiencies. Treatment of hemorrhagic diatheses due to hyperfibrinolysis occurs with antifibrinolytic agents such as tranexamic acid or e-aminocaproic acid. These are lysine analogues that block the lysinebinding sites of plasminogen, inhibiting binding of plasminogen to fibrin, leading to decreased plasminogen activation [12] . In this review, we will discuss the main disorders of fibrinolysis causing a bleeding tendency and their associated clinical implications, laboratory diagnosis and treatment. 
a2-antiplasmin deficiency
Background a2-antiplasmin (a2-AP) is the main physiological inhibitor of plasmin [2] . The deficiency can lead to the abundant presence of plasmin and therefore induce hyperfibrinolysis and bleeding. a2-AP is a member of the serpin family of enzyme inhibitors, and it is synthesized in the liver [13] . The gene for a2-AP is located on chromosome 17 [14] . The first case of a2-AP deficiency was published in 1978 in a patient with post-traumatic as well as spontaneous bleeding. The deficiency was then named Miyasoto disease after the patient's surname. By studying the family, it was noted that this disorder was most likely inherited autosomal recessive [15] . The prevalence of a2-AP deficiency is unknown, but it is very rare.
Clinical manifestations An overview of bleeding symptoms in patients with a homozygous a2-AP deficiency can be found in Fig. 4 . [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] These numbers were extracted from 14 cases. A homozygous deficiency usually leads to serious bleeding symptoms, mostly post-trauma and postsurgery or after dental extractions. A few of the included patients in Fig. 4 (A) did not have a hemostatic challenge; therefore, the prevalence of 43% post-surgery bleeding is likely to be an underestimate, as well as the percentages for post-trauma and post-dental extraction bleeding. Only three adult women have been described with a homozygous a2-AP deficiency. Therefore, the prevalence of menorrhagia could not be calculated. However, two of these three women experienced menorrhagia so it appears to be a relevant issue [17, 24, 29] . Interestingly, multiple patients have been described with intramedullary hematomas, an uncommon type of bleeding [21, 22] .
A total of 104 individuals with a heterozygous a2-AP deficiency were found. These individuals either had bleeding symptoms or were family members of a known homozygous patient [17, 19, 20, 24, [26] [27] [28] [29] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . Sixty-six of 104 heterozygous individuals were asymptomatic. The number of symptomatic heterozygous individuals is likely to be an overestimate caused by publication bias. Interestingly, severe bleeding tendencies such as gastrointestinal bleeding and umbilical cord bleeding have also been described in individuals with a heterozygous a2-AP deficiency [31, 38] . The most common bleeding symptoms in individuals with a heterozygous a2-AP deficiency were post-surgery and post-traumatic. Although the occurrence of menorrhagia and postpartum bleeding could not be calculated, because many articles do not give details on whether participants were male or female, these symptoms appear to occur quite often as well [34, 36, 38, 40, 42] . All of the heterozygous individuals had a2-AP levels of around 50%. A study in patients with acquired a2-AP deficiency showed that clinical hyperfibrinolysis only occurred at plasma levels of a2-AP below 60% [46] . It is unknown whether women with a heterozygous a2-AP deficiency experience high rates of obstetric complications, as almost no adult women with pregnancies have been described. There are some reports of relevant obstetric bleeding complications in both homozygous and two heterozygous women, leading to miscarriage and preterm delivery [29, 34, 38] . In summary, homozygous a2-AP deficiency is associated with a severe bleeding tendency and possibly a high rate of female-specific bleeding problems. Bleeding manifestations in individuals with a heterozygous a2-AP deficiency are less often described in the literature; however, they do occur.
Diagnosis and treatment Ignorance about a2-AP deficiency might lead to underestimation of the diagnosis. This can be aggravated by the lack of abnormalities in screening assays. The euglobulin clot lysis time is usually shortened but can be normal in both carriers and homozygous patients [15, [17] [18] [19] [20] 23, 25, 26, 31, 33, 37, 38] . A reason for this low sensitivity for a2-AP deficiency can be the lack of enrichment of a2-AP in the euglobulin fraction after acidification of plasma [47] . When a deficiency is suspected based on a shortened clot lysis time and/or suspicious history, directed a2-AP confirmation assays should be performed. A deficiency can be either quantitative (type I), causing a coincidental decrease in a2-AP activity and antigen, or qualitative (type II), causing low activity levels with normal or only slightly decreased antigen concentrations [12] . The treatment of bleeding episodes consists of antifibrinolytic agents. Antifibrinolytic agents can also be used as prophylaxis before invasive procedures [12, 13] . The use of fresh frozen plasma (FFP) has also been described; however, the variable activity of a2-AP in FFP and the possible adverse event of introducing dilutional coagulopathy as a result of volume overload make this a less attractive option [12, 13, 35] . Currently, in many countries, FFP is being replaced by omniplasma; however, omniplasma has lower a2-AP levels and shorter ROTEM lysis times with a reduction of more than 50% when compared to FFP. Therefore, the use of omniplasma is not recommended in the treatment of a2-AP deficiency [48] . Desmopressin acetate may induce secretion of plasminogen activator and should therefore be avoided [35] .
Plasminogen activator inhibitor type 1 deficiency
Background Plasminogen activator inhibitor type 1 (PAI-1) is the principal inhibitor of tPA and uPA [2] . Like a2-AP, PAI-1 is a member of the serpin family [2] . A variety of cells synthesize PAI-1, including hepatocytes, adipocytes and endothelial cells [49] . The PAI-1 gene is located on chromosome 7, and its expression can be induced by several factors such as insulin [50] . Although the principal function of PAI-1 is inhibition of fibrinolysis, it has other functions in inflammation as an acute phase protein. In contrast to low PAI-1 levels, high PAI-1 levels are associated with atherosclerosis and coronary artery disease, metabolic syndrome, fibrosis and poor prognoses in several cancer types [51] . When evaluating a patient for PAI-1 deficiency, both antigen and activity levels should be analyzed, as the deficiency can be both qualitative or quantitative. The first case of a bleeding disorder as a result of a qualitative PAI-1 deficiency was described by Schleef et al. in 1989, followed by the first reported quantitative deficiency in 1991 [52, 53] . It is an autosomal recessive disorder [54] . The prevalence of PAI-1 deficiency is not known as it has only been described in case reports. However, two studies showed that the incidence of PAI-1 activity < 1.0 U mL À1 and < 2.0 U mL À1 in healthy populations was as high as 10-13% and 21%, respectively [55, 56] . These data suggest that many individuals with low PAI-1 activity are asymptomatic. The prevalence of a bleeding disorder caused by PAI-1 deficiency is low. However, accurate diagnosis is hampered by a lack of accuracy of the currently available activity assays in the lowest range [50] .
Clinical manifestations The bleeding tendency of patients with a PAI-1 deficiency is shown in Fig. 4 (B) [30, [52] [53] [54] [55] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] . A total of 36 patients with a PAI-1 deficiency have been described, including both qualitative and quantitative deficiencies. Most patients experienced post-trauma and post-surgery bleeding. Two cases could not be included in the analysis of this review, because aside from their PAI-1 deficiency, they also had another disorder that could explain their specific bleeding symptoms, and both of the articles did not report any other symptom [76, 77] . When only taking into account the 17 women ≥ 12 years of age that have been described, nine of them experienced menorrhagia, making this a common symptom. Obstetric complications appear to occur often in women with a PAI-1 deficiency. The reason for this is not entirely clear, although animal studies have suggested that PAI-1 and the accompanying proteolytic process play a role in degradation of the follicular wall during ovulation, as well as in fertilization, embryo implantation, embryogenesis and angiogenesis [54, 78] . A total of 17 described pregnancies and outcomes were found. As shown in Fig. 5 , there is a high rate of miscarriage and preterm birth, with only 24% of described pregnancies reaching term. Vaginal bleeding during pregnancy was common, occurring in 54%, as well as postpartum bleeding, with a prevalence of 27% [54, 65, 67, 69, 70, 73] . These numbers might be an overestimation as a result of publication bias. However, in the case of missing information about bleeding complications, pregnancies were considered as being normal to compensate for the possible overestimation bias. Family investigation revealed only symptoms in a minority of the heterozygous family members [58, 59, 63, 66] . However, Del Rosario et al. described a heterozygous individual with severe bleeding symptoms including spontaneous hemarthrosis [79] . In summary, homozygous PAI-1 deficiency is associated with major bleeding problems and obstetric complications, whereas heterozygous PAI-1 deficiency is usually asymptomatic.
Diagnosis and treatment
The actual diagnosis of a PAI-1 deficiency is often delayed as a result of normal screening tests and impaired recognition of the disorder. The currently available assays for PAI-1 activity are not discriminative in the lowest range, as the normal limit of these assays ranges to zero [50] . PAI-1 antigen levels are even more difficult to interpret, as these assays do not discriminate between complexed PAI-1 and free PAI-1. Furthermore, the diurnal variation of PAI-1, with highest levels in the early morning and lowest in the afternoon, can make accurate diagnosis more complicated [80] . The diagnosis of PAI-1 deficiency is further complicated by the fact that the euglobulin clot lysis time is not always shortened despite the fact that PAI-1 is enriched in the euglobulin fraction [52, 53, 60, 61, 63, 64, 66, 70, 73] . In addition, tPA activity can be high; however, a normal value does not exclude the diagnosis [52, 58, 61, 63, 71, 72] . Treatment of PAI-1 deficiency consists of antifibrinolytics. They can be used as treatment for an acute bleeding, as a preventive measure before an invasive procedure and for limiting the amount of menstrual blood loss or epistaxis [50, 59, 70] .
Urokinase-type plasminogen activator excess
Background The Quebec platelet disorder (QPD) is the only described disorder with hyperfibrinolysis caused by excess of urokinase-type plasminogen activator (uPA). It is caused by a tandem duplication of a 78-kb genomic segment that includes the PLAU gene, leading to overexpression of uPA. It is an autosomal dominant disorder with a high penetrance [81] . Most known cases have been traced to a single family of French ancestry in Quebec, Canada [82] . The hyperfibrinolysis is caused by increased expression and storage of uPA in platelets [83] . The genetic defect causes increased transcription of the PLAU allele during megakaryocyte differentiation located on chromosome 10 [84] . The first case was described in 1984, although at the time bleeding was thought to be caused by a qualitative platelet factor V deficiency. Therefore, the disorder was first called factor V Quebec [85] . The prevalence of the disorder worldwide is unknown; however, in Canada it is estimated at 1 : 655 000 and in Quebec 1 : 220 000 [86] .
Clinical manifestations The bleeding history of the QPD family has been described in detail by McKay et al [82] . Twenty-three patients with the disorder were described (see Fig. 4C for their bleeding symptoms). As in the other fibrinolytic disorders, bleeding after dental extractions, surgery and trauma was frequently reported. A total of nine pregnancies were described, none of which ended in miscarriage. None of the patients reported antenatal bleeding; however, two women needed transfusion after giving birth. As in PAI-1 deficiency, some patients reported impaired wound healing, which was associated with lower platelet counts [82] . One separate case of QPD from Pakistan was not included in the review, because the diagnosis was only based on reduced aggregation with epinephrine. Although often seen in QPD, this is not considered specific for this disorder [87] .
Diagnosis and treatment As this disorder is autosomal dominant with a high penetrance, the family history will be positive most of the time and raise a suspicion in cases of bleeding. The disorder is characterized by increased platelet content of uPA, which is released upon platelet activation. In a resting condition, uPA in plasma is normal or only moderately increased [81] . The disorder can be accompanied by an unexplained mild thrombocytopenia [85, 88] . Screening assays for coagulation are usually normal, although factor (F) V can be mildly deficient. Platelet FV is reduced [85] . Functional platelet tests often reveal a characteristic pattern of absent aggregation with epinephrine and a reduced platelet aggregation with ADP and collagen, probably because of the overexpression of uPA and subsequent activation of plasminogen in platelets. Plasmin then can degrade von Willebrand factor, FV and fibrinogen [81, 88] . Whole-blood clot lysis time is normal and urinary uPA is not increased [89, 90] . As the genetic defect has been unraveled and other diagnostics are variable and complicated, it is now recommended to perform a PCR assay for the QPD mutation when diagnosis is suspected [91] . Patients with bleeding complications should be treated with antifibrinolytic therapy. The administration of platelets does not reduce bleeding [88, 90] .
Tissue-type plasminogen activator excess
As previously mentioned, patients with a congenital PAI-1 deficiency may have high levels of tPA activity, with most of the time normal tPA antigen levels [52, 58, 61, 63, 71, 72] . A total of four cases have been described with high levels of plasminogen activator and a bleeding tendency [92] [93] [94] . These patients had symptoms of excessive bleeding after trauma and surgery, and in some cases also spontaneous hematomas or easy bruising. Family members of a patient with an excess of tPA had high tPA levels and shortened euglobulin clot lysis time, without any bleeding symptoms [93] . One of the patients underwent liver transplantation for cirrhosis and was thereby cured of his bleeding disorder [94] . In addition, an abstract by Hampton et al. described a family of 12 members who showed elevated plasma activator levels, of whom nine had a history of excessive bleeding [95] . As a few of the above-mentioned cases of tPA excess were diagnosed before the discovery of PAI-1 deficiency in 1989, these cases can be misdiagnosed. However, two cases had normal PAI-1 activity and antigen level [93, 94] . Given the sparse number of cases, it is currently unclear whether this can be considered a separate entity within the bleeding disorders. For diagnosis we recommend the use of an activity assay rather than an antigen assay, as currently available antigen assays do not only measure the free form but also complexes between tPA and PAI-1.
Acquired disorders of fibrinolysis
Acquired disorders of fibrinolysis are an important cause of bleeding and mortality. In acute promyelocytic leukemia (APL), a deficiency of a2-AP or TAFI or excess of uPA can contribute to the bleeding tendency [46, 96, 97] . Fibrinolysis can be further increased in these patients as a result of high levels of annexin A2 expression on APL cells, leading to increased production of plasmin [98] . In cirrhosis, high levels of tPA as well as deficiency of a2-AP and TAFI have been described [99] . However, this may be rebalanced by a decline in antifibrinolytic factors, and typical hyperfibrinolytic bleeding in cirrhotic patients is rare [100] . In addition, acquired a2-AP deficiency has been described in a variety of diseases, including amyloidosis, gastric cancer, prostatic cancer, adenocarcinomas and nephrotic syndrome (as a result of renal loss) [46, 99, [101] [102] [103] . Trauma is also associated with high fibrinolytic activity, and a higher fibrinolytic activity correlates with a poor clinical outcome in these patients [104] . In addition, there are also iatrogenic causes of hyperfibrinolysis. Cardiopulmonary bypass provokes a state of hyperfibrinolysis caused by rapid thrombin generation and high circulating levels of epinephrine, bradykinin and vasopressin [105] . Thrombolysis, increasingly used for ischemic stroke and other indications, is also an important cause of iatrogenic hyperfibrinolysis. Risk factors for post-thrombolytic bleeding include advanced age, female gender and low bodyweight. For patients with a high risk of major bleeding, weight-adjusted doses and catheter-directed therapy should be considered to reduce the risk [106] . Post-thrombolytic bleeding can be converted using reversal agents, especially in the case of intracranial bleeding <24 h after thrombolysis or ongoing coagulopathy demonstrated by hypofibrinogenemia. Possible reversal agents include cryoprecipitate, recombinant FVIIa, FFP or antifibrinolytic agents. Other options may be considered in specific patient groups (e.g. prothrombin complex concentrate in patients on vitamin K antagonists) [107] . Theoretically, omniplasma and fibrinogen concentrate are options for conversion as well; however, they have not been described in the literature for this indication.
Fibrinolysis in bleeding of unknown cause
There is a substantial number of patients with a bleeding tendency and positive family history for bleeding complications without a definite diagnosis after performing all available screening tests and conformational tests. Conceivably, there will be a subset of patients with a hyperfibrinolytic disorder amongst them. In addition, several studies have demonstrated an altered fibrinolytic balance in patients with a bleeding tendency of unknown cause. In a study of 270 patients with bleeding of unknown cause, patients had higher tPA activity levels and lower levels of tPA-PAI-1 complexes and lower PAI-1 levels, indicating a possible underlying hyperfibrinolytic disorder [5] . In a cohort of patients undergoing cardiac surgery, postoperative blood loss was associated with lower preoperative levels of PAI-1 and lower postoperative tPA-PAI-1 levels [108] . On the other hand, a study evaluating fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause showed no differences in PAI-1 levels between patients and healthy controls. In addition, low PAI-1 activity levels are common in a normal population and there is no significant difference between PAI-1 activity levels in patients with a bleeding tendency compared with blood donors and healthy controls [5, 56] .
Conclusions
Although the prevalence of hyperfibrinolytic disorders as a cause of bleeding described in the literature is quite low, the bleeding tendency is usually characterized by a pattern of delayed bleeding upon trauma or surgery and mucocutaneous bleeding such as menorrhagia and epistaxis. However, a clinical differentiation with other bleeding disorders, such as platelet disorders or von Willebrand disease, can be difficult, as they frequently present with mucocutaneous bleeding as well. Bleeding complications caused by fibrinolytic disorders can be very severe and can lead to increased morbidity and mortality if not treated adequately with antifibrinolytic therapy.
In general, the group of fibrinolytic disorders can be divided into patients with excess of stimulators of fibrinolysis and patients with a deficiency of inhibitors. The most severe clinical phenotype is caused by a2-AP deficiency. It is noteworthy that PAI-1 deficiency is accompanied by obstetric complications through a still unexplained underlying mechanism. Concerning the other fibrinolytic disorders, the occurrence of obstetric complications is as yet unknown and therefore an interesting subject for future research.
Because of the lack of recognition of fibrinolytic disorders and the difficulties in assessing the right diagnosis, the prevalence of these disorders is probably higher than described thus far. An accurate diagnosis is severely hampered by the absence of a sensitive and validated test of fibrinolysis. This accounts for the PAI-1 antigen and activity level, but also for the euglobulin clot lysis time. Normal results of these tests do not rule out a hyperfibrinolytic disorder. Furthermore, these current fibrinolytic assays can only be undertaken in specialized laboratories. Global assays may overcome this problem as, in general, these assays are more sensitive and able to measure several pathways in just one test. Examples are assays that measure plasmin generation or plasma-based turbidity assays [109, 110] . A disadvantage is that these assays are not widely available. Moreover, next-generation sequencing techniques of genes involving the whole spectrum of coagulation may contribute to the unraveling of suspected fibrinolytic disorders.
Fibrinolytic assays in patients with bleeding of unknown cause show inconclusive results. Overall, an imbalance in the fibrinolytic system could be the explanation for a bleeding tendency more often than currently anticipated, and more research in this field would be beneficial. Finally, without a proper and accurate diagnosis, bleeding complications cannot be treated with targeted therapy, leading to unnecessary use of inappropriate blood products and expensive factor concentrates. We suggest developing or validating new diagnostic tools to better monitor fibrinolysis in order to facilitate the use of adequate therapy for bleeding as a result of malfunctioning of the fibrinolytic cascade.
Recommendations for clinical practice
-Disorders of fibrinolysis should not be routinely tested for in patients with a bleeding tendency, because they are rare and laboratory diagnostics unreliable -Fibrinolysis assays should be undertaken in a specialized laboratory when there is a high index of suspicion, raised by: recurrent abnormal bleeding, mainly delayed bleeding post-trauma/surgery and mucocutaneous bleeding positive family history of an established hyperfibrinolytic disorder co-occurrence with reproductive failure unusual bleeding sites (e.g. intramedullary hematomas or umbilical cord bleeding) -In the future, diagnostics may be improved by the implementation of thrombin and plasmin generation assays and genetic tests using next-generation sequencing 
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